# Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

> **NCT00314977** · PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00314977
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2010-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314977, "Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00314977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*